Home > Boards > US Listed > Biotechs > Aurinia Pharmaceuticals Inc (AUPH)

AMRN reportedly looking at an “authorized generic” version

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 219
Posts 17,388
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Aurinia Pharmaceuticals reverses decline after report on potential M&A interest Seeking Alpha - 1/13/2022 2:49:28 PM
Aurinia Pharmaceuticals drops amid silence on M&A after conference presentations Seeking Alpha - 1/13/2022 12:57:53 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 1/7/2022 4:11:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2022 4:19:20 PM
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences Business Wire - 1/4/2022 4:17:00 PM
ICE Biotech index rejig: AUPH, AVXL among added; AMRS, GH among deleted Seeking Alpha - 12/17/2021 11:54:46 AM
Aurinia: Long Term Prospects Are Sound, Says Oppenheimer TipRanks - 12/13/2021 3:14:19 PM
Aurinia Pharma upgraded at Oppenheimer; ongoing M&A story noted Seeking Alpha - 12/10/2021 8:23:48 AM
Aurinia Pharmaceuticals nearing highs on report about M&A process Seeking Alpha - 12/9/2021 1:25:51 PM
Aurinia gains 7% on positive Lupkynis data in lupus nephritis study Seeking Alpha - 12/9/2021 6:30:44 AM
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) Business Wire - 12/9/2021 6:15:00 AM
Aurinia Pharmaceuticals gains amid takeover speculation Seeking Alpha - 12/2/2021 11:06:41 AM
Aurinia falls 28% amid mixed shelf offering, skepticism on buyout rumors Seeking Alpha - 11/22/2021 12:43:00 PM
Aurinia Pharmaceuticals drops 12% after filing mixed shelf offering Seeking Alpha - 11/19/2021 5:26:12 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 11/19/2021 5:05:35 PM
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference Business Wire - 11/10/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2021 4:21:48 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/3/2021 4:14:03 PM
Aurinia Pharma slips as uptake of lupus nephritis therapy slows Seeking Alpha - 11/3/2021 8:28:18 AM
Aurinia Pharma EPS misses by $0.06, beats on revenue Seeking Alpha - 11/3/2021 6:11:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/3/2021 6:02:00 AM
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates Business Wire - 11/3/2021 6:00:00 AM
Aurinia Pharma Q3 2021 Earnings Preview Seeking Alpha - 11/2/2021 11:59:17 AM
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis Business Wire - 11/1/2021 10:12:00 AM
Aurinia Pharma drops after GlaxoSmithKline denies report on potential bid Seeking Alpha - 11/1/2021 10:01:23 AM
north40000 Member Level  Tuesday, 09/15/20 05:25:35 PM
Re: zzaatt post# 11076
Post # of 14707 
AMRN reportedly looking at an “authorized generic” version of Vascepa, in addition to branded version. Same drug and label, 2 different names and prices(Brand Vascepa for reduction of risk of CVD is $36/year out of pocket for me since mid-2018). Let’s see whether and how generics compete—no entry into market place yet in the Marine market. Generics hope for off label prescriptions and sales into CVD space; Marine market/revenue is relatively small.

Vascepa also has a statutory exclusivity (resulting from FDA approving its sNDA for results in CVDs demonstrated in 8000+ patient Reduce-It trial last 12/2020) that expires 12/2022. It is independent of any RI patents (numbering >40-50 at last count) that expire 2030 and later.

Our LTCG in Amarin far exceeds our LTCG in AUPH(we have 65x more shares of AMRN than 2k AUPH). Basis for AUPH shares = $1.94.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences